Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Short Interest Down 84.1% in July

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF – Get Free Report) saw a significant decrease in short interest in the month of July. As of July 31st, there was short interest totaling 55,796 shares, a decrease of 84.1% from the July 15th total of 350,806 shares. Based on an average daily volume of 2,500 shares, the days-to-cover ratio is currently 22.3 days.

Analyst Upgrades and Downgrades

Separately, Danske initiated coverage on shares of Hansa Biopharma AB (publ) in a report on Tuesday, June 16th. They set a “buy” rating for the company. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy”.

Get Hansa Biopharma AB (publ) alerts:

View Our Latest Research Report on HNSBF

Hansa Biopharma AB (publ) Stock Performance

Shares of HNSBF remained flat at $3.70 during midday trading on Friday. Hansa Biopharma AB has a 1-year low of $2.90 and a 1-year high of $3.70. The company has a 50-day simple moving average of $3.08 and a 200-day simple moving average of $2.96.

About Hansa Biopharma AB (publ)

(Get Free Report)

Hansa Biopharma AB (publ) is a clinical‐stage biopharmaceutical company headquartered in Lund, Sweden, focused on the development and commercialization of precision immunomodulatory therapies for rare diseases. The company’s proprietary platform centers on highly specific bacterial enzymes that selectively cleave immunoglobulin G (IgG) antibodies, offering a novel approach to desensitization and immunomodulation in transplant and autoimmune settings.

The lead asset, imlifidase (Idefirix), is an enzyme therapeutic designed to rapidly inactivate donor‐specific antibodies in highly sensitized kidney transplant patients.

Featured Stories

• Five stocks we like better than Hansa Biopharma AB (publ)
• Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
• Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
• NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
• Sandisk’s Margins Look Like Software. Can They Last?

Receive News & Ratings for Hansa Biopharma AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hansa Biopharma AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.